… and to assess nirmatrelvir/ritonavir efficacy against SARS-… (≥18 years) who were experiencing
COVID-19 for the first time and … that COVID-19 patients receiving nirmatrelvir/ritonavir had …

… Furthermore, using a standardized approach, we predicted potential DDIs with
nirmatrelvir/ritonavir for a comprehensive list of comedications likely to be prescribed in COVID-19 …

… , particularly as compared with nirmatrelvir–ritonavir. In addition, the … nirmatrelvir–ritonavir
for oral treatment of symptomatic participants at high risk for progression to severe Covid-19 …

… , nirmatrelvir–ritonavir (Paxlovid™), for the treatment of patients with mild‐to‐moderate
COVID‐19 … the efficacy and safety of nirmatrelvir–ritonavir in COVID‐19 patients, and explore the …

… We identified 13 ongoing studies investigating nirmatrelvir/ritonavir for treatment of COVID‐19,
which may change the findings of the review or the certainty of evidence, and broaden the …

… recurrence of COVID symptoms associated with new positive lateral flow tests in
immunosuppressed adults at high risk of severe COVID-19 treated with nirmatrelvir/ritonavir. The …

… nirmatrelvir–ritonavir treatment for COVID-19. At present, the difference in efficacy and safety
between nirmatrelvir–ritonavir … of nirmatrelvir–ritonavir treatment for COVID-19 compared …

… decrease in the rate of severe COVID-19 (adjusted HR 0.54; … for the patients treated with
nirmatrelvir/ritonavir with respect to … of COVID-19 receiving molnupiravir or nirmatrelvir/ritonavir. …

… Nirmatrelvir targets SARS-CoV-2’s main protease, and it is combined with ritonavir to delay
its metabolism and allow nirmatrelvir … due to COVID-19, molnupiravir and nirmatrelvir/ritonavir …

… the difficulty with outpatient therapeutic drug monitoring, nirmatrelvir-ritonavir will be
challenging to use in most transplant recipients with COVID-19. This may also be enhanced by the …